Methods and Devices for Detecting Glomerulonephritis and Associated Disorders

a glomerulonephritis and associated disorder technology, applied in the field of methods and devices for diagnosing, monitoring or determining glomerulonephritis or an associated disorder in a mammal, can solve the problems of inability to detect the disease, the kidney is especially vulnerable to injury, and the test is also generally costly, slow, and/or invasiv

Inactive Publication Date: 2011-03-17
MYRIAD RBM INC
View PDF21 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006]The present invention provides methods and devices for diagnosing, monitoring, or determining a renal disorder in a mammal. In particular, the present invention provides metho...

Problems solved by technology

Because compounds in circulation are concentrated in the kidney up to 1000-fold relative to the plasma concentration, the kidney is especially vulnerable to injury due to exposure to toxic compounds.
Oth...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and Devices for Detecting Glomerulonephritis and Associated Disorders
  • Methods and Devices for Detecting Glomerulonephritis and Associated Disorders
  • Methods and Devices for Detecting Glomerulonephritis and Associated Disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Least Detectable Dose and Lower Limit of Quantitation of Assay for Analytes Associated with Renal Disorders

[0093]To assess the least detectable doses (LDD) and lower limits of quantitation (LLOQ) of a variety of analytes associated with renal disorders, the following experiment was conducted. The analytes measured were alpha-1 microglobulin (A1M), beta-2 microglobulin (B2M), calbindin, clusterin, CTGF, cystatin C, GST-alpha, KIM-1, NGAL, osteopontin (OPN), THP, TIMP-1, TFF-3, and VEGF.

[0094]The concentrations of the analytes were measured using a capture-sandwich assay using antigen-specific antibodies. For each analyte, a range of standard sample dilutions ranging over about four orders of magnitude of analyte concentration were measured using the assay in order to obtain data used to construct a standard dose response curve. The dynamic range for each of the analytes, defined herein as the range of analyte concentrations measured to determine its dose response curve, is presented ...

example 2

Precision of Assay for Analytes Associated with Renal Disorders

[0101]To assess the precision of an assay used to measure the concentration of analytes associated with renal disorders, the following experiment was conducted. The analytes measured were alpha-1 microglobulin (A1M), beta-2 microglobulin (B2M), calbindin, clusterin, CTGF, cystatin C, GST-alpha, KIM-1, NGAL, osteopontin (OPN), THP, TIMP-1, TFF-3, and VEGF. For each analyte, three concentration levels of standard solution were measured in triplicate during three runs using the methods described in Example 1. The percent errors for each run at each concentration are presented in Table 3 for all of the analytes tested:

TABLE 3Precision of Analyte AssayAverageRun 1Run 2Run 2InterrunconcentrationErrorErrorErrorErrorAnalyte(ng / mL)(%)(%)(%)(%)Calbindin4.0626133653272811603Clusterin4.449263951682291302CTGF1.210174142.5191914141875139GST-alpha3.91475101613710114211668KIM-10.035205130.3245282.90574VEGF65101614534921275,397113149β-2 ...

example 3

Linearity of Assay for Analytes Associated with Renal Disorders

[0103]To assess the linearity of an assay used to measure the concentration of analytes associated with renal disorders, the following experiment was conducted. The analytes measured were alpha-1 microglobulin (A1M), beta-2 microglobulin (B2M), calbindin, clusterin, CTGF, cystatin C, GST-alpha, KIM-1, NGAL, osteopontin (OPN), THP, TIMP-1, TFF-3, and VEGF. For each analyte, three concentration levels of standard solution were measured in triplicate during three runs using the methods described in Example 1. Linearity of the assay used to measure each analyte was determined by measuring the concentrations of standard samples that were serially-diluted throughout the assay range. The % recovery was calculated as observed vs. expected concentration based on the dose-response curve. The results of the linearity analysis are summarized in Table 4.

TABLE 4Linearity of Analyte AssayExpectedObservedRecoveryAnalyteDilutionconcentra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the priority of U.S. provisional application Ser. No. 61 / 327,389, filed Apr. 23, 2010, and U.S. provisional application Ser. No. 61 / 232,091, filed Aug. 7, 2009, each of which is hereby incorporated by reference in its entirety and is related to U.S. patent application Nos. [Not Yet Assigned], entitled Methods and Devices for Detecting Obstructive Uropathy and Associated Disorders, Computer Methods and Devices for Detecting Kidney Damage, Methods and Devices for Detecting Kidney Damage, Devices for Detecting Renal Disorders, Methods and Devices for Detecting Kidney Transplant Rejection, Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders, Attorney Docket Nos. 060075-, filed on the same date as this application, the entire contents of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The invention encompasses methods and devices for diagnosing, monitoring, or determini...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/48G01N33/70G01N33/68
CPCG01N33/6893G01N2800/34Y10T436/147777G01N33/566G01N33/5302G01N2333/47G01N2333/4703G01N2333/4706G01N2333/4725G01N2333/4727G01N2333/475G01N2333/52G01N2333/70503G01N2333/70539G01N2333/765G01N2333/775G01N2333/8139G01N2333/8146G01N2333/82G01N2333/91177G01N2800/347G01N2800/52G01N2800/56G01N2800/60
Inventor LABRIE, SAMUEL T.MAPES, JAMES P.MCDADE, RALPH L.EISINGER, DOMINIC P.BALLARD, KARRI L.SPAIN, MICHAEL D.
Owner MYRIAD RBM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap